KRAS and melanoma: To test this hypothesis, we first confirmed that treatment of three oncogene-driven cancer models (EGFR mutant NSCLC, BRAF mutant melanoma, and KRAS mutant PDAC) with their cognate inhibitors (the EGFR inhibitor gefitinib, the BRAF inhibitor PLX4720, and the ERK inhibitor VX-11e, respectively) resulted in changes to the mitochondrial network morphology (Fig. 6a, b, Supplementary Fig. 6a).